SIRT1 and metabolic disease: In addition, CK2-mediated phosphorylation of SIRT1 at the Ser164 site inhibits its nuclear localization and promotes the progress of non-alcoholic fatty liver (Choi et al., 2017), which provides evidence that SIRT1 is involved in the improvement of metabolic diseases.